|
 |
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print May 1, 2007
J. Lipid Res., doi:10.1194/jlr.P600011-JLR200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 48, 1190-1203, May 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology
Patient-Oriented Research |
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions
* Department of Nutrition, Harvard School of Public Health, Boston, MA 02115
Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan 105-8461
The online version of this article (available at http://www.jlr.org) contains supplementary data.
Published, JLR Papers in Press, February 21, 2007.
1 Present address of C. Khoo: Hill's Pet Nutrition, Topeka, KS 66617.
2 To whom correspondence should be addressed. e-mail: fsacks{at}hsph.harvard.edu
ABSTRACT
The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL + intermediate density lipoprotein) generally cites the action of apolipoprotein C-III (apoC-III), a component of some TRLs, to retard their metabolism in plasma. We studied the kinetics of multiple TRL and LDL subfractions according to the content of apoC-III and apoE in 11 hypertriglyceridemic and normolipidemic persons. The liver secretes mainly two types of apoB lipoproteins: TRL with apoC-III and LDL without apoC-III. Approximately 45% of TRLs with apoC-III are secreted together with apoE. Contrary to expectation, TRLs with apoC-III but not apoE have fast catabolism, losing some or all of their apoC-III and becoming LDL. In contrast, apoE directs TRL flux toward rapid clearance, limiting LDL formation. Direct clearance of TRL with apoC-III is suppressed among particles also containing apoE. TRLs without apoC-III or apoE are a minor, slow-metabolizing precursor of LDL with little direct removal. Increased VLDL apoC-III levels are correlated with increased VLDL production rather than with slow particle turnover. Finally, hypertriglyceridemic subjects have significantly greater production of apoC-III-containing VLDL and global prolongation in residence time of all particle types. ApoE may be the key determinant of the metabolic fate of atherogenic apoC-III-containing TRLs in plasma, channeling them toward removal from the circulation and reducing the formation of LDLs, both those with apoC-III and the main type without apoC-III.
Supplementary key words kinetics • stable isotopes • apolipoprotein B-100 • apolipoprotein E • low density lipoprotein
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. O. Mendivil, C. Zheng, J. Furtado, J. Lel, and F. M. Sacks Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sundaram, S. Zhong, M. B. Khalil, P. H. Links, Y. Zhao, J. Iqbal, M. M. Hussain, R. J. Parks, Y. Wang, and Z. Yao Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions J. Lipid Res., January 1, 2010; 51(1): 150 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. van Schalkwijk, A. A. de Graaf, B. van Ommen, K. van Bochove, P. C. N. Rensen, L. M. Havekes, N. C. A. van de Pas, H. C. J. Hoefsloot, J. van der Greef, and A. P. Freidig Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size J. Lipid Res., December 1, 2009; 50(12): 2398 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hiukka, M. Stahlman, C. Pettersson, M. Levin, M. Adiels, S. Teneberg, E. S. Leinonen, L. M. Hulten, O. Wiklund, M. Oresic, et al. ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan Diabetes, September 1, 2009; 58(9): 2018 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kawakami, M. Osaka, M. Tani, H. Azuma, F. M. Sacks, K. Shimokado, and M. Yoshida Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction Circulation, August 12, 2008; 118(7): 731 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zheng, C. Khoo, J. Furtado, K. Ikewaki, and F. M Sacks Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III Am. J. Clinical Nutrition, August 1, 2008; 88(2): 272 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Scheffer, T. Teerlink, J. M. Dekker, G. Bos, G. Nijpels, M. Diamant, P. J. Kostense, C. D. A. Stehouwer, and R. J. Heine Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study Clin. Chem., August 1, 2008; 54(8): 1325 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D Furtado, H. Campos, L. J Appel, E. R Miller, N. Laranjo, V. J Carey, and F. M Sacks Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial, Am. J. Clinical Nutrition, June 1, 2008; 87(6): 1623 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism J. Lipid Res., March 1, 2008; 49(3): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |